Abstract Details

Title Safety and Efficacy of Percutaneous Transluminal Angioplasty for Atherosclerotic Stenosis of Vertebral Artery Origin

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P16 - Poster Session 16 (5:30 PM-6:30 PM)

Poster/Presentation
Number 4-007

Objective The aim was to find out how the presence of severe impairment of other cerebral feeding arteries and concomitant carotid artery stenting (CAS) affected the periprocedural risk and long-term effect of percutaneous transluminal angioplasty (PTA) for atherosclerotic stenosis of vertebral artery origin (VAO).

Background Data on frequency of concurrent impairment of other cerebral feeding arteries and the risk of PTA both alone and with stent placement (PTAS) of VAO stenosis in this situation are very limited.

Design/Methods We used a retrospective analysis of consecutive balloon angioplasties for ≥70% VAO stenosis. The patients were divided into groups with an isolated VAO stenosis and multiple stenoses. We investigated the frequency of periprocedural complications in the first 72 h and the risk of developing restenosis and ischemic stroke/transient ischemic attack (TIA) during the follow-up period.

Results In the set of 66 patients aged 66.1±9.1 years, concurrent severe polystenotic impairment was present in 56 (84.8%) patients. 21 (31.8%) patients received endovascular treatment for a stenosis on one or more other arteries in addition to VAO stenosis (15 of them had CAS). In the periprocedural period, none of the patients suffered from ischemic stroke or died. One case of TIA in the carotid artery territory (1.6%) occurred in the polystenotic group with concurrent CAS. During the mean follow-up period of 36 months, we identified 8 cases (16.3%) of ≥50% asymptomatic VA restenosis. In addition, 4 (8.9%) cases of ischemic stroke occurred in the polystenotic group.

Conclusions The presence of a severe polystenotic impairment or concomitant CAS had no adverse effects on the overall low periprocedural risk of balloon angioplasty of VAO stenosis or the risk of developing restenosis during the follow-up period.

Authors/Disclosures
Roman Herzig, MD, PhD (Palacky University, Faculty of Medicine and Dentistry) PRESENTER	Roman Herzig, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca. Roman Herzig, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Boehringer Ingelheim . Roman Herzig, MD, PhD has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Care Comm.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Oldrich Vysata	No disclosure on file
	No disclosure on file
Martin Valis, MD	Dr. Valis has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Valis has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Valis has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva.

��ɫ��

��ɫ��